HGH Fragment 176-191 is a synthetic peptide derived from the C-terminal end of human growth hormone (hGH) and is widely recognized for its targeted lipolytic, or fat-burning, effects. This peptide, often nicknamed the “lipolytic fragment,” is specifically engineered to stimulate fat loss while avoiding many of the unwanted side effects typically associated with full-length hGH, such as increased IGF-1 levels, long bone growth, and shifts in insulin sensitivity.
 
What is HGH Fragment 176-191?
HGH Fragment 176-191 is a modified segment of natural hGH, designed based on AOD9604, comprising the amino acid sequence Phe–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe. With a molecular formula of C78H123N23O22S2 and a molecular weight of 1799.1 g/mol, this fragment represents the precise portion of hGH responsible for fat metabolism, stripped of the regions that cause collateral effects.
Key Benefits (For Research Use)
Promotes fat breakdown in adipose tissue by stimulating beta-3 adrenergic receptors, directly boosting energy expenditure in laboratory models.
Has been shown in animal studies to lower blood sugar levels by increasing plasma insulin, potentially opening doors for prediabetes and type 2 diabetes research.
May aid cartilage regeneration when combined with hyaluronic acid, as indicated by studies in rabbit models of osteoarthritis.
Demonstrates a selective action: robust weight loss in genetically obese research models, with minimal effect on lean subjects, highlighting its targeted mechanism.
Research Highlights
Fat Loss and Weight Reduction: Animal studies indicate significant reduction in weight gain in obese models, with up to 50% less fat accumulation over three weeks.
No Growth Hormone Adverse Effects: Unlike full-length hGH, Fragment 176-191 does not increase IGF-1, does not promote long bone growth, and does not alter insulin sensitivity in studies.
Cartilage Regeneration: Recent preclinical research suggests potential synergistic effects with hyaluronic acid, supporting cartilage repair and potentially reducing disability from osteoarthritis.
Safety Data
A 2013 meta-analysis of six high-standard clinical studies indicated that HGH Fragment 176-191 did not result in changes in physical findings, laboratory parameters, glucose tolerance, IGF-1 levels, or increased rates of adverse effects compared to placebo. These results suggest that, in controlled research settings, Fragment 176-191 retains the beneficial properties of hGH while minimizing risk. Importantly, this peptide lacks the anabolic (muscle-building) effects of hGH, making it uniquely suited for studies focusing on specific metabolic pathways.
Specifications
Content: 6mg of lyophilized HGH Fragment 176-191 peptide per vial
Sequence: Phe–Leu–Arg–Ile–Val–Gln–Cys–Arg–Ser–Val–Glu–Gly–Ser–Cys–Gly–Phe
Molecular Formula: C78H123N23O22S2
CAS Number: 66004-57-7
Purity: >98% (as confirmed by HPLC)
Storage: Store in a cool, dry place. Reconstituted peptide should be stored as per laboratory protocols.
Intended Use
HGH Fragment 176-191 is presented for academic and laboratory research only. It is not intended for human or animal consumption and should only be handled by qualified professionals. Any bodily introduction is strictly prohibited by law.
Compliance Disclaimer
This product is furnished for in-vitro research only. It has not been evaluated or approved by the FDA for medical use, treatment, or diagnosis. PeptidesAlpha does not provide medical advice, and this product is not for personal use.
For high-purity research peptides with superior standards and reliable sourcing, trust PeptidesAlpha – advancing scientific discovery with excellence.